Amneal Pharmaceuticals, Financials
| AMRX Stock | USD 8.53 0.36 4.05% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.45 | 1.4054 |
|
|
Investors should never underestimate Amneal Pharmaceuticals,'s ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Amneal Pharmaceuticals,'s cash flow, debt, and profitability to make informed and accurate decisions about investing in Amneal Pharmaceuticals, Class.
Net Income |
|
Amneal | Select Account or Indicator |
Understanding current and past Amneal Pharmaceuticals, Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Amneal Pharmaceuticals,'s financial statements are interrelated, with each one affecting the others. For example, an increase in Amneal Pharmaceuticals,'s assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Amneal Pharmaceuticals,'s accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Amneal Pharmaceuticals, Class. Check Amneal Pharmaceuticals,'s Beneish M Score to see the likelihood of Amneal Pharmaceuticals,'s management manipulating its earnings.
Amneal Pharmaceuticals, Stock Summary
Amneal Pharmaceuticals, competes with Alkermes Plc, Neurocrine Biosciences, Intracellular, Dynavax Technologies, and Amphastar. Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey. Amneal Pharmaceuticals operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on New York Stock Exchange. It employs 7000 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | New York Stock Exchange |
| ISIN | US03168L1052 |
| CUSIP | 03168L105 |
| Business Address | 400 Crossing Boulevard, |
| Sector | Pharmaceuticals |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.amneal.com |
| Phone | 908 947 3120 |
| Currency | USD - US Dollar |
Amneal Pharmaceuticals, Key Financial Ratios
| Return On Equity | -8.81 | ||||
| Profit Margin | (0.04) % | ||||
| Operating Margin | 0.11 % | ||||
| Price To Sales | 1.39 X | ||||
| Revenue | 2.79 B |
Amneal Pharmaceuticals, Key Balance Sheet Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Total Assets | 4.0B | 3.9B | 3.8B | 3.5B | 3.5B | 3.2B | |
| Other Current Liab | 459.8M | 495.8M | 481.0M | 475.4M | 630.8M | 317.2M | |
| Other Liab | 35.7M | 87.3M | 48.5M | 97.1M | 111.7M | 75.0M | |
| Net Tangible Assets | (1.6B) | (1.5B) | (1.4B) | (1.4B) | (1.2B) | (1.3B) | |
| Net Debt | 2.6B | 2.6B | 2.8B | 2.7B | 220.8M | 209.8M | |
| Retained Earnings | (286.8M) | (276.2M) | (406.2M) | (490.2M) | (607.1M) | (576.7M) | |
| Accounts Payable | 154.1M | 132.9M | 166.8M | 143.6M | 258.7M | 228.6M | |
| Cash | 341.4M | 247.8M | 26.0M | 91.5M | 110.6M | 147.9M | |
| Other Assets | 16.5M | 149.3M | 473.7M | 17.6M | 20.3M | 19.3M | |
| Long Term Debt | 2.7B | 2.7B | 2.6B | 2.4B | 2.2B | 2.2B | |
| Net Receivables | 674.2M | 662.6M | 741.8M | 613.7M | 775.7M | 616.9M | |
| Good Will | 522.8M | 593.0M | 598.9M | 598.6M | 597.4M | 422.5M | |
| Long Term Debt Total | 2.7B | 2.7B | 2.7B | 2.6B | 3.0B | 2.1B | |
| Capital Surpluse | 607.0M | 628.4M | 658.4M | 691.6M | 795.4M | 648.3M | |
| Inventory | 490.6M | 489.4M | 530.7M | 581.4M | 612.5M | 476.1M | |
| Other Current Assets | 80.5M | 120.3M | 113.3M | 91.2M | 89.1M | 86.6M | |
| Total Liab | 3.7B | 3.6B | 3.6B | 3.5B | 3.6B | 3.2B | |
| Short Long Term Debt | 45.2M | 30.6M | 90.0M | 213.1M | 324.2M | 340.4M | |
| Total Current Assets | 1.6B | 1.5B | 1.4B | 1.4B | 1.6B | 1.3B | |
| Short Term Debt | 57.5M | 46.0M | 104.6M | 227.6M | 240.3M | 252.3M | |
| Intangible Assets | 1.3B | 1.2B | 1.1B | 890.4M | 732.4M | 920.5M | |
| Common Stock | 3.0M | 3.0M | 3.0M | 3.1M | 3.1M | 3.2M |
Amneal Pharmaceuticals, Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Interest Expense | 146.0M | 136.3M | 158.4M | 210.6M | 258.6M | 134.8M | |
| Total Revenue | 2.0B | 2.1B | 2.2B | 2.4B | 2.8B | 1.8B | |
| Gross Profit | 628.4M | 769.0M | 784.7M | 820.6M | 1.0B | 716.5M | |
| Operating Income | 91.2M | 209.2M | 206.5M | 204.4M | 249.3M | 129.7M | |
| Ebit | 145.7M | 216.6M | (89.8M) | 170.4M | 203.6M | 126.3M | |
| Research Development | 190.6M | 209.6M | 200.0M | 167.8M | 196.6M | 201.8M | |
| Ebitda | 381.0M | 450.0M | 150.4M | 399.8M | 439.8M | 338.0M | |
| Cost Of Revenue | 1.4B | 1.3B | 1.4B | 1.6B | 1.8B | 1.1B | |
| Income Before Tax | (35.8M) | 31.4M | (248.1M) | (40.3M) | (55.0M) | (52.3M) | |
| Net Income | 68.6M | 20.2M | (254.8M) | (84.0M) | (116.9M) | (111.0M) | |
| Income Tax Expense | (104.4M) | 11.2M | 6.7M | 8.5M | 18.9M | 33.7M | |
| Minority Interest | (22.5M) | 9.5M | (125.2M) | (35.3M) | (43.0M) | (40.9M) | |
| Tax Provision | (104.4M) | 11.2M | 6.7M | 8.5M | 18.9M | 28.0M | |
| Net Interest Income | (146.0M) | (136.3M) | (158.7M) | (251.4M) | (258.6M) | (245.7M) | |
| Non Recurring | 107.6M | 21.6M | 35.3M | 288.7M | 332.0M | 348.6M |
Amneal Pharmaceuticals, Key Cash Accounts
Cash flow analysis captures how much money flows into and out of Amneal Pharmaceuticals,. It measures of how well Amneal is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Amneal Pharmaceuticals, brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Amneal had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Amneal Pharmaceuticals, has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change To Inventory | (113.8M) | (49.0M) | (102.4M) | (126.2M) | (130.5M) | (124.0M) | |
| Change In Cash | 194.3M | (90.4M) | (221.5M) | 63.9M | 19.3M | 20.3M | |
| Net Borrowings | (27M) | 175.9M | (1M) | 83.3M | 75.0M | 71.3M | |
| Free Cash Flow | 312.8M | 189.2M | (25.5M) | 276.4M | 243.2M | 255.3M | |
| Depreciation | 235.4M | 233.4M | 240.2M | 229.4M | 236.2M | 164.4M | |
| Other Non Cash Items | 20.0M | 10.0M | 107.8M | 185.3M | 105.0M | 54.5M | |
| Capital Expenditures | 66.2M | 52.6M | 90.6M | 69.2M | 51.9M | 69.9M | |
| Net Income | 68.6M | 20.2M | (254.8M) | (48.7M) | (73.9M) | (70.2M) | |
| End Period Cash Flow | 347.1M | 256.7M | 35.2M | 99.1M | 118.4M | 152.2M | |
| Change To Netincome | 655.8M | 128.2M | 112.5M | 132.1M | 151.9M | 170.7M | |
| Investments | (317.5M) | (194.2M) | (174.3M) | (69.2M) | (63.0M) | (66.1M) | |
| Change Receivables | (133.7M) | 17.2M | (16.3M) | (80.1M) | (72.1M) | (68.5M) |
Amneal Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Amneal Pharmaceuticals,'s current stock value. Our valuation model uses many indicators to compare Amneal Pharmaceuticals, value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Amneal Pharmaceuticals, competition to find correlations between indicators driving Amneal Pharmaceuticals,'s intrinsic value. More Info.Amneal Pharmaceuticals, Class is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Amneal Pharmaceuticals,'s Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Amneal Pharmaceuticals,'s earnings, one of the primary drivers of an investment's value.Amneal Pharmaceuticals, Systematic Risk
Amneal Pharmaceuticals,'s systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Amneal Pharmaceuticals, volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on Amneal Pharmaceuticals, correlated with the market. If Beta is less than 0 Amneal Pharmaceuticals, generally moves in the opposite direction as compared to the market. If Amneal Pharmaceuticals, Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Amneal Pharmaceuticals, is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Amneal Pharmaceuticals, is generally in the same direction as the market. If Beta > 1 Amneal Pharmaceuticals, moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Amneal Pharmaceuticals, Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Amneal Pharmaceuticals,'s growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Amneal Pharmaceuticals, growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Amneal Pharmaceuticals, March 27, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Amneal Pharmaceuticals, help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Amneal Pharmaceuticals, Class. We use our internally-developed statistical techniques to arrive at the intrinsic value of Amneal Pharmaceuticals, Class based on widely used predictive technical indicators. In general, we focus on analyzing Amneal Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Amneal Pharmaceuticals,'s daily price indicators and compare them against related drivers.
| Downside Deviation | 2.09 | |||
| Information Ratio | 0.0474 | |||
| Maximum Drawdown | 9.89 | |||
| Value At Risk | (3.73) | |||
| Potential Upside | 3.46 |
Additional Tools for Amneal Stock Analysis
When running Amneal Pharmaceuticals,'s price analysis, check to measure Amneal Pharmaceuticals,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amneal Pharmaceuticals, is operating at the current time. Most of Amneal Pharmaceuticals,'s value examination focuses on studying past and present price action to predict the probability of Amneal Pharmaceuticals,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amneal Pharmaceuticals,'s price. Additionally, you may evaluate how the addition of Amneal Pharmaceuticals, to your portfolios can decrease your overall portfolio volatility.